GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Price-to-Funds-From-Operations

ADCT (ADC Therapeutics) Price-to-Funds-From-Operations : (As of Mar. 23, 2025)


View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


ADC Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.